Yahoo HomeHow To: Oil pull using coconut oil
Can swishing coconut oil in your mouth actually improve your oral hygiene?
Make Yahoo Your Homepage
Discover something new every day from News, Sports, Finance, Entertainment and more!
Can swishing coconut oil in your mouth actually improve your oral hygiene?
Demonstrators gathered in Berlin on Wednesday to protest against a law parliament is set to pass giving the national government power to impose lockdowns on areas with high coronavirus infection rates to curb a third wave of the pandemic. Chancellor Angela Merkel decided to draw up the new law, which has drawn criticism from opponents who argue it curtails personal freedoms, after some of Germany's 16 federal states refused to impose tough measures despite a surge in cases. Thousands of protesters are expected to demonstrate against the law outside the Bundestag parliament building in central Berlin.
Russian President Vladimir Putin delivered his annual address to the nation Wednesday amid a sweeping Kremlin crackdown on opposition protests and soaring tensions with the West. Putin began his state-of-the-nation speech by hailing the nation's response to the coronavirus pandemic. Putin proposed new incentives to help the economy overcome the blow from the pandemic and new social payments to the population.
Barney is a bit different from your usual Swiss bartender. Developer F & P Robotics says it is seeing rising interest in "The Barney Bar" and hopes it will be a hit among hotels, bars and shopping centres looking to reduce human contact during and after the coronavirus pandemic. Barney can mix 16 different spirits and eight different sodas for customers who place their orders via their mobile phones, as well as offering beer and prosecco.
Detroit Pistons (18-40) vs. Dallas Mavericks (30-26): 8:30 p.m.; American Airlines Center in Dallas; Bally Sports Detroit-Plus; 950 AM
Dublin, April 21, 2021 (GLOBE NEWSWIRE) -- The "North America Ginseng Extracts Market By Application (Pharmaceuticals, Food & Beverages, Dietary Supplements and Cosmetics & Personal Care), By Form (Powder and Liquid), By Country, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering. The North America Ginseng Extracts Market is expected to witness market growth of 8.2% CAGR during the forecast period (2020-2026).Ginseng is a plant characterized by having a single stalk and fleshy roots. It is a perennial plant and has a longer lifespan. Ginseng is an example of herbal supplements and extracts obtained from it. These are commercially in huge demand, mainly for its exceptional and extraordinary health benefits. It possesses anti-inflammatory, anti-cancer, and antioxidant properties. It is also used in the homeopathic medicines that are used for the treatment of depression, stress, attention deficit, hyperactivity disorder, and low libido.The use of ginseng started approximately 4,500 years ago, and its first written evidence are of 2,000 years ago. Depending on the consumer's preferences, ginseng is used as agricultural products, dietary supplements, food, health supplements, and medicines, etc. The red ginseng health supplements are mostly consumed in the forms of ginseng powder, capsules, tablets, concentrated extracts, pills, granules, soft capsule beverages, candy, etc.Ginseng extract in dietary supplements strengthens the resistance of the body to fight illness by boosting the immune system. The use of herbs as a substitute remedy to conservative therapy has been a matter of concern for the health professionals. It is highly beneficial for those individuals whose immune system is moderately compromised or selective resistant treatment is necessary to reduce the adverse events.Based on Application, the market is segmented into Pharmaceuticals, Food & Beverages, Dietary Supplements and Cosmetics & Personal Care. Based on Form, the market is segmented into Powder and Liquid. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Clariant AG, Orkla ASA, Sinochem Group Co., Ltd., RFI Ingredients, LLC, Shanti Natural Extracts, Hangzhou Skyherb Technologies Co., Ltd., S.A. Herbal Bioactives LLC, Changsha Huir Biological-Tech Co., Ltd., Baoji Herbest Bio-Tech Co., Ltd. and Liuyang Naturalin Bio-Tech Co., Ltd. Unique Offerings from the Publisher Exhaustive coverageHighest number of market tables and figuresSubscription based model availableGuaranteed best priceAssured post sales research support with 10% customization free Key Topics Covered: Chapter 1. Market Scope & Methodology1.1 Market Definition1.2 Objectives1.3 Market Scope1.4 Segmentation1.4.1 North America Ginseng Extracts Market, by Application1.4.2 North America Ginseng Extracts Market, by Form1.4.3 North America Ginseng Extracts Market, by Country1.5 Methodology for the researchChapter 2. Market Overview2.1 Introduction2.1.1 Overview2.1.2 Market composition and scenario2.2 Key Factors Impacting the Market2.2.1 Market Drivers2.2.2 Market RestraintsChapter 3. North America Ginseng Extracts Market by Application3.1 North America Pharmaceuticals Market by Country3.2 North America Food & Beverages Market by Country3.3 North America Dietary Supplements Market by Country3.4 North America Cosmetics & Personal Care Market by CountryChapter 4. North America Ginseng Extracts Market by Form4.1 North America Powder Market by Country4.2 North America Liquid Market by CountryChapter 5. North America Ginseng Extracts Market by Country5.1 US Ginseng Extracts Market5.1.1 US Ginseng Extracts Market by Application5.1.2 US Ginseng Extracts Market by Form5.2 Canada Ginseng Extracts Market5.2.1 Canada Ginseng Extracts Market by Application5.2.2 Canada Ginseng Extracts Market by Form5.3 Mexico Ginseng Extracts Market5.3.1 Mexico Ginseng Extracts Market by Application5.3.2 Mexico Ginseng Extracts Market by Form5.4 Rest of North America Ginseng Extracts Market5.4.1 Rest of North America Ginseng Extracts Market by Application5.4.2 Rest of North America Ginseng Extracts Market by FormChapter 6. Company Profiles6.1 Clariant AG6.1.1 Company Overview6.1.2 Financial Analysis6.1.3 Research & Development Expense6.1.4 Recent strategies and developments:6.1.4.1 Product Launches and Product Expansions:6.2 Orkla ASA6.2.1 Company Overview6.2.1 Financial Analysis6.2.2 Segmental and Regional Analysis6.2.3 Research & Development Expenses6.3 Sinochem Group Co., Ltd.6.3.1 Company Overview6.3.2 Financial Analysis6.3.3 Segmental and Regional Analysis6.4 RFI Ingredients, LLC6.4.1 Company Overview6.5 Shanti Natural Extracts6.5.1 Company Overview6.6 Hangzhou Skyherb Technologies Co., Ltd.6.6.1 Company Overview6.7 S.A. Herbal Bioactives LLC6.7.1 Company Overview6.8 Changsha Huir biological tech Co., Ltd.6.8.1 Company Overview6.9 Baoji Herbest Bio-Tech Co., Ltd.6.9.1 Company Overview6.10. Liuyang Naturalin Bio-Tech Co., Ltd.6.10.1 Company OverviewFor more information about this report visit https://www.researchandmarkets.com/r/hcngzt CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
(2021-04-21) Kitron ASA held its Annual General Meeting on 21 April 2021. 47 961 395 shares, amounting to 26.78 per cent of the share capital, were represented at the meeting. All proposals were resolved as presented in the notice issued on 31 March 2021. After the general meeting, the board of Kitron comprises the following shareholder and employee elected members: Shareholder elected members:Tuomo Lähdesmäki (Chairman, re-elected)Gro Brækken (re-elected)Espen Gundersen (re-elected)Maalfrid Brath (re-elected)Christian Jebsen (re-elected)Petra Grandinson (re-elected) Employee elected members:Bjørn GottschlichTanja RørheimJarle Larsen The Annual General Meeting approved the proposed dividend of NOK 0.70 per share in two tranches of (i) NOK 0.35 per share for shareholders registered in Kitron’s shareholder register with the Norwegian Central Securities Depository (VPS) as of expiry of 23 April 2021 and (ii) NOK 0.35 per share for shareholders registered in Kitron’s shareholder register with the VPS as of expiry of 6 October 2021, based on normal T+2 settlements. Kitron's shares will be traded on the Oslo Stock Exchange exclusive the right to receive dividends for tranche (i) from 22 April 2021 and for tranche (ii) from 5 October 2021. The dividends for tranche (i) are expected to be paid on or about 3 May 2021 and for tranche (ii) on or about 22 October 2021. The minutes from the Annual General Meeting are attached. For further information, please contact:Cathrin Nylander, CFO, tel: +47 900 43 284E-mail: investorrelations@kitron.com Kitron is a leading Scandinavian electronics manufacturing services company for the Connectivity, Electrification, Industry, Medical devices and Defence/Aerospace sectors. The company is located in Norway, Sweden, Lithuania, Germany, Poland, China and the United States. Kitron had revenues of about NOK 4.0 billion in 2020 and has about 1 800 employees. www.kitron.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment 2021 Minutes from Ordinary General meeting
Kering Société anonyme with a capital of € 500,071,664 Head office : 40, rue de Sèvres – 75007 PARIS 552 075 020 RCS PARIS April 21, 2021 Statement in compliance with article 223-16 of the General Regulation of the French Financial Markets Authority (AMF – Autorité des Marchés Financiers) Date Total Number of shares Total number of voting rights theoretical 1 Exercisable 2 April 15, 2021 125,017,916 177,788,897 177,663,897 1 Calculated based on all shares with voting rights, including treasury shares stripped of voting rights (Art. 223-11 of AMF General Regulations). 2 Excluding treasury shares stripped of voting rights. Attachment Kering - Statement Number of Shares and voting rights - 04.15.2021
Abstract: - Global Tumor / Cancer Markers Market to Reach $3. 7 Billion by 2027. - Amid the COVID-19 crisis, the global market for Tumor / Cancer Markers estimated at US$2.New York, April 21, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Tumor / Cancer Markers Industry" - https://www.reportlinker.com/p06033174/?utm_source=GNW 1 Billion in the year 2020, is projected to reach a revised size of US$3.7 Billion by 2027, growing at a CAGR of 8.1% over the period 2020-2027. - The U.S. Market is Estimated at $575.1 Million, While China is Forecast to Grow at 12.2% CAGR - The Tumor / Cancer Markers market in the U.S. is estimated at US$575.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$835.2 Million by the year 2027 trailing a CAGR of 12.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 7.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR. - Select Competitors (Total 35 Featured) - Abbott Diagnostics Ltd.Affymetrix, Inc.Agilent Technologies, Inc.Beckman, Dickinson and Company (BD) DiagnosticsBioCurexBioModa, Inc.Clarient, Inc.Correlogic Systems, Inc.Epigenomics AGGen-Probe, Inc. Read the full report: https://www.reportlinker.com/p06033174/?utm_source=GNW I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Tumor / Cancer Markers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 2: World Historic Review for Tumor / Cancer Markers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 3: World 15-Year Perspective for Tumor / Cancer Markers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027 III. MARKET ANALYSIS UNITED STATES Table 4: USA Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 5: USA Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR CANADA Table 6: Canada Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 7: Canada Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR JAPAN Table 8: Japan Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 9: Japan Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR CHINA Table 10: China Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 11: China Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR EUROPE Table 12: Europe Current & Future Analysis for Tumor / Cancer Markers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 13: Europe Historic Review for Tumor / Cancer Markers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 14: Europe 15-Year Perspective for Tumor / Cancer Markers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027 FRANCE Table 15: France Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 16: France Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR GERMANY Table 17: Germany Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 18: Germany Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR ITALY Table 19: Italy Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 20: Italy Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR UNITED KINGDOM Table 21: UK Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 22: UK Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR SPAIN Table 23: Spain Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 24: Spain Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR RUSSIA Table 25: Russia Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 26: Russia Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR REST OF EUROPE Table 27: Rest of Europe Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 28: Rest of Europe Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR ASIA-PACIFIC Table 29: Asia-Pacific Current & Future Analysis for Tumor / Cancer Markers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 30: Asia-Pacific Historic Review for Tumor / Cancer Markers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 31: Asia-Pacific 15-Year Perspective for Tumor / Cancer Markers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027 AUSTRALIA Table 32: Australia Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 33: Australia Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR INDIA Table 34: India Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 35: India Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR SOUTH KOREA Table 36: South Korea Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 37: South Korea Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR REST OF ASIA-PACIFIC Table 38: Rest of Asia-Pacific Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 39: Rest of Asia-Pacific Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR LATIN AMERICA Table 40: Latin America Current & Future Analysis for Tumor / Cancer Markers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 41: Latin America Historic Review for Tumor / Cancer Markers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 42: Latin America 15-Year Perspective for Tumor / Cancer Markers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027 ARGENTINA Table 43: Argentina Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 44: Argentina Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR BRAZIL Table 45: Brazil Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 46: Brazil Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR MEXICO Table 47: Mexico Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 48: Mexico Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR REST OF LATIN AMERICA Table 49: Rest of Latin America Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 50: Rest of Latin America Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR MIDDLE EAST Table 51: Middle East Current & Future Analysis for Tumor / Cancer Markers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 52: Middle East Historic Review for Tumor / Cancer Markers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 53: Middle East 15-Year Perspective for Tumor / Cancer Markers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027 IRAN Table 54: Iran Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 55: Iran Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR ISRAEL Table 56: Israel Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 57: Israel Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR SAUDI ARABIA Table 58: Saudi Arabia Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 59: Saudi Arabia Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR UNITED ARAB EMIRATES Table 60: UAE Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 61: UAE Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR REST OF MIDDLE EAST Table 62: Rest of Middle East Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 63: Rest of Middle East Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR AFRICA Table 64: Africa Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 65: Africa Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR IV. COMPETITION Total Companies Profiled: 35Read the full report: https://www.reportlinker.com/p06033174/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
With over £40 worth of beauty buys inside.
Singer Destiny Chukunyere will return to the stage this year to represent her native Malta at the Eurovision Song Contest. The artist is no stranger to Eurovision glory, having won the content's 2015 junior edition with "Not My Soul," marking Malta's first victory. Destiny's latest track, a feel-good, dancefloor filler titled "Je Me Casse," has been selected as Malta's entry for Eurovision's 2021 comeback.
Germany's top court has refused to issue an injunction blocking the country's participation in the European Union's 750 billion-euro (more than $900 billion) coronavirus recovery fund, clearing the way for the launch of the fund and its common borrowing aimed at supporting green and digital economic development. The Federal Constitutional Court said Wednesday it turned back a motion for a preliminary injunction from a group including economics professor Bernd Lucke, a founder of the populist Alternative for Germany who has since left the party.
The University of Virginia Health System said this week it will cancel decades of court judgments and liens over unpaid medical bills from low-income patients. The big picture: The decision would likely benefit tens of thousands of families and would make UVA Health's collection policy way more lenient than those of many other hospital systems, Kaiser Health News reports. Get market news worthy of your time with Axios Markets. Subscribe for free.Details: The cancellation will apply to patients who are at or below 400% of the federal poverty level. This includes a patient who makes less than $51,520 or someone in a family of four who makes $106,000 or less.The health system will also stop blocking enrollment for university students with outstanding balances.UVA Health also said it is in the process of establishing an ombudsperson’s office to help patients determine manageable payment options and to impartially assess an individual’s medical costs. Background: UVA Health said last year it would no longer sue future patients over medical bills. Reforms came after KHN published an investigation in 2019 that found UVA Health had sued patients 36,000 times over a period of six years for more than $100 million. Like this article? Get more from Axios and subscribe to Axios Markets for free.
Tech-enabled insurance provider Oscar Health just launched its tech platform for payers and providers, called +Oscar, but the company still faces some steep hurdles.Driving the news: +Oscar is a standalone business that expands on previous partnerships. The company is selling it to everyone from other payers looking to improve their consumer experiences to medical groups looking to jump into value-based care arrangements.Get market news worthy of your time with Axios Markets. Subscribe for free.“We built Oscar from day one with an eye towards using our technology to power as much of the healthcare ecosystem as possible,” Meghan Joyce, who was just named head of +Oscar, told Axios.What we're hearing: "In theory, theory, you should be able to sell that to other health plans. It should work," said Charles Rhyee, a managing director and senior research analyst at Cohen.. "I think the question is: 'How quickly?'"Yes, but: Oscar has gotten a lot of buzz for its promise to shake up the industry, but has yet to turn a profit. Its share price has seen a steep drop since its IPO last month and fell again on Tuesday.Oscar gets the vast majority of its premium revenue from the Affordable Care Act's insurance exchanges. Increasing competition in those marketplaces — including United Healthcare and Aetna's plans to reenter the exchanges — will likely eat into Oscar's margins.Like this article? Get more from Axios and subscribe to Axios Markets for free.
"The queen has not let her age stop her doing those events she can. There’s no evidence she’s not going to continue," said one royal expert.
The raging new wave of the COVID-19 pandemic in India has caused producer ZEE Studios to change its film releasing strategy. “Radhe: Your Most Favourite Bhai,” the latest vehicle for Bollywood superstar Salman Khan will not be released in theaters alone, but instead be distributed simultaneously across multiple platforms. The film will release theatrically worldwide, […]
EdiGene, Inc. ("Company", or "EdiGene"), today announced the successful completion of an RMB 400 million (approximately USD 62 million) Series B Plus financing. Loyal Valley Capital led the round and other new investors included BioTrack Capital and Sherpa Healthcare Partners, along with continued support by existing investors including IDG Capital, Lilly Asia Venture, 3H Health Investment, Huagai Capital, Sequoia Capital China, Alwin Capital and Kunlun Capital. EdiGene is a biotech company develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases. Previously the company completed a Series B Financing of an RMB 450 million (approximately USD 67 million) in October 2020. Proceeds from the financing will be used to advance the company’s pipeline into clinics and to scale up the business operation.
N'DJAMENA, April 21 (Reuters) - Rebel forces set their sights on Chad's capital N'Djamena on Wednesday following the battlefield death of President Idriss Deby, threatening to bring more disruption to a country vital to international efforts to combat Islamist militants in Africa. Schools and some businesses were open in N'Djamena on Wednesday but many people had opted to stay home and the streets were quiet, a Reuters witness said.
Galderma is uniting rosacea sufferers from around the globe in an empowering social media awareness movement during Rosacea Awareness Month (April): #RosaceaUnmasked.
Apr. 21—At the Cobb Board of Commissioners' monthly zoning hearing Tuesday, four of the board's five members overruled the Cobb Planning Commission's decision to hold a rezoning application earlier this month. Though the matter was not formally voted on, Chairwoman Lisa Cupid was clear she did not agree with the "exacting" move by the board. Commissioners sought to rezone a piece of ...
Google is working on improvements for its WebView apps and plans to release more updates for the software and Chrome in order to avoid a repeat of last month's Android crash.